The authors concluded that insulin pen devices were a preferred and more acceptable insulin delivery system than conventional vial and syringe. The authors' conclusions represented the evidence presented, but the lack of study quality assessment made the reliability of the conclusions unclear.
Study selection
Eligible for inclusion in the review were studies of children, adolescents and/or adults with type 1 and/or type 2 diabetes that compared insulin pen use to vial and syringe use. Studies needed to be controlled for confounding and other types of bias and evaluate patient preference and/or patient-reported outcomes as either primary or secondary outcomes.
Half of the included studies contained patients with type 1 diabetes. Mean age of patients was 45 years (range eight to 79 years). Insulin pen devices were manufactured by Eli Lilly, Novo Nordisk A/S, Becton Dickinson and Company and Sanofi-Aventis. Half of the studies were industry sponsored. Patient-reported outcomes included: flexibility, acceptability, treatment satisfaction, preference, quality of life, ease of use, convenience and handling/dosing and pain. Patient-reported outcomes were assessed with a variety of questionnaires; half of the included studies used an unspecified questionnaire. Study designs included single group pre/post test, retrospective cohort and randomised crossover trials.
Two reviewers independently performed selection. Any disagreements were resolved by discussion or involvement of a third reviewer.
Assessment of study quality
The authors did not state whether study quality was assessed.
Data extraction
Main study attributes (study design, country, patient-reported outcomes, results) were extracted into a data summary table.
Two reviewers independently extracted results data and reported results as either more favourable for pen, more favourable for vial/syringe or no difference/mixed results.
